United States: Healthcare Law Update: March 2017

Nathan Adam IV is a Partner in the Tallahassee office

Matthew Goldfarb is an Associate in the Chicago office

Courtney Groh and David Glynn are Partners and Andrew Namkung and Ilenna Stein are Associates in the Boston office

Enforcement

OIG Issues Advisory Opinion Allowing Free or Reduced-Cost Lodging and Meals

By Courtney Groh and Andrew Namkung

On March 3, 2017, the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG) issued Advisory Opinion 17-01 (Opinion) allowing an academic medical center's (Requestor's) proposal to provide free or reduced-cost lodging and meals to qualifying financially needy patients (Program). The Opinion is the first advisory opinion to expound upon the so-called "Promotes Access to Care" exception (Exception) under the OIG's Dec. 7, 2017, Final Rule.

Specifically, the Requestor proposed to provide up to three nights of free or reduced-cost hotel lodging and a hospital cafeteria meal allowance for patients who satisfy the following criteria: 1) the patient resides more than 90 miles from the hospital in a medically underserved or health professional shortage area; 2) the patient's household income does not exceed 500 percent of the federal poverty level; and 3) the patient's hospital appointment is before 10:00 a.m. and/or the patient has a follow-up appointment within 48 hours of an initial treatment. The Requester stated that it would not advertise the Program and would pay the vendor (e.g., the hotel) directly.

Applying a two-prong test, the OIG determined, first, that the Program would promote access to care through the removal of socioeconomic and geographic barriers that could prevent patients from receiving treatment. Second, the OIG concluded that the Program posed a low risk of harm to patients and federal healthcare programs for the following reasons: 1) the Program is unlikely to interfere with clinical decision-making, as eligibility for the Program is not dependent on the receipt of any particular service and clinicians are not compensated for referring patients to the hospital; 2) there is no risk of increased federal costs (e.g., overutilization), as the arrangement is not advertised and patients are only selected after the treatment is scheduled; and 3) the arrangement does not raise patient safety or quality-of-care concerns, and instead is intended to remove obstacles preventing patients from obtaining necessary treatment.

The OIG also recognized that the arrangement would implicate the Anti-Kickback Statute (AKS). Although the civil monetary penalty (CMP) exceptions do not apply to the AKS, the OIG concluded that, based on the same factors cited in the analysis of the Exception, the Requestor would not be subject to administrative sanctions under the AKS in connection with the arrangement.

Antitrust

Anthem-Cigna Merger Blocked Due to Antitrust Concerns

By Matthew Goldfarb

In United States v. Anthem, Inc., No. 16-1493, 2017 WL 685563 (D. DC. Feb. 21, 2017), the U.S. District Court for the District of Columbia issued an order blocking the proposed merger between Anthem and Cigna. The court held that the U.S. Department of Justice, 11 states and the District of Columbia (together, the Plaintiffs), met their burden of showing that the effect of the merger "may be to substantially lessen competition in the market for sales to national accounts [defined as 'customers with more than 5,000 employees, usually spread over at least two states']." In concluding that the merger would violate federal antitrust laws, the court held that the market for the sale of health insurance to national accounts is a "properly drawn market for purposes of antitrust laws, and that the fourteen states in which Anthem enjoys the exclusive right to compete under the Blue Cross Blue Shield banner, compromise a relevant geographic market for the product." Next, the court held that "plaintiffs established that the high level of concentration in the national accounts market that would result from the merger is "presumptively unlawful under the U.S. Department of Justice and Federal Trade Commission Horizontal Merger Guidelines" and that the merger is likely to have other anticompetitive effects, including: "eliminat[ion] of [Anthem and Cigna's] competition against each other for national accounts, reduc[tion] in the number of national carriers available to respond to solicitations in the future, and diminish[ing] of the prospects for innovation in the market." Anthem filed an Emergency Motion for Expedited Consideration of Appeal with the U.S. Court of Appeals for the District of Columbia Circuit, which was subsequently granted on Feb. 17, 2017.

Market Allocation Agreements Are Not Per Se Antitrust Violations

By Nathan Adams

In Procaps, S.A. v. Patheon, Inc., 845 F. 3d 1072 (11th Cir. 2016), the court of appeals affirmed final summary judgment in the defendant's favor on the grounds that the plaintiff failed to show concerted action as necessary to maintain a Sherman Act Section 1 claim or to adduce concrete evidence of actual anticompetitive effects under a rule of reason analysis. The parties to the lawsuit were joint venturers. Procaps, S.A. (Procaps) designs and manufactures gel capsules in Colombia for delivery of medications. Patheon, Inc. (Patheon) has longstanding relationships with American pharmaceutical companies and a strong marketing operation. In January 2012, the two decided to pool their attributes to create a new, more effective competitor in the American softgel market by entering into a collaboration agreement. In October 2012, Patheon informed Procaps of its planned acquisition of Banner Pharmacaps (Banner), an American designer and manufacturer of gel capsules. Procaps refused to participate in the collaboration any longer and sued Patheon for an antitrust violation. Procaps argued that the collaboration agreement, although lawful at its inception, was transformed into an illegal restraint of trade by Patheon's acquisition of Banner. The court of appeals disagreed on the grounds that Procaps never made a conscious commitment to a common scheme to illegally restrain trade under the collaboration agreement; rather, it quit participating in the agreement, so there was no concerted action under the agreement to restrain trade. The combination with Banner was wholly unilateral by Patheon. Procaps also argued that the court supply apply a per se rule and condemn the post-acquisition agreement as a horizontal market allocation agreement between competitors, but the court of appeals ruled that just because an agreement can be characterized as a market allocation agreement does not mean that the per se rule applies. Under the rule of reason analysis, Procaps failed to show any actual evidence of a reduction in output, increase in price or deterioration in quality.

Deceptive Trade Practices

New York Hospital States DTPA Claim against Insurer

By Nathan Adams

In Icahn Sch. of Med. At Mt. Sinai v. Health Care Serv. Corp., No. 16-cv-8756 (JSR), 2017 WL 635648 (S.D. N.Y. Feb. 15, 2017), the court granted an insurer's motion to dismiss a hospital's claim for negligent misrepresentation, but denied the motion as to the hospital's claims for violation of New York's deceptive business practice statute, GBL §349, and promissory estoppel. The hospital is "out-of-network" with respect to the insurer. The hospital claims that before treating Health Care Service Corp. (HCSC)-insured patients, it contacts the insurer to verify coverage and determine the methodology that the insurer will utilize to determine the amount that it will pay to the hospital. The hospital then allegedly transmits this information to the insured. The hospital filed suit against the insurer after six occasions in which the insurer allegedly told the hospital that it would reimburse the hospital using a particular rate, but ultimately paid significantly less. As to the deceptive trade practice claim, the insurer alleged that the hospital failed to show "consumer-oriented conduct" by the hospital or that the challenged acts or practices have a broader impact on consumers at large. Although acknowledging that the hospital is not itself a consumer, the court rejected the insurer's argument because the hospital transmitted the insurer's alleged misrepresentations to patients during pretreatment consultation so that they could make an informed decision whether to proceed with treatment. The court also disagreed with the insurer that the hospital failed to show a false representation or reasonable reliance as necessary to state a claim for promissory estoppel. But the court did find that the hospital failed to allege facts showing that the insurer had a duty, as a result of a special relationship, to give correct information to the hospital, as necessary to prove negligent misrepresentation.

Regulation and Legislation

OIG Encouraged to Develop New AKS Safe Harbors to Protect Value-Based Arrangements

By David Glynn and Ilenna Stein

The HHS OIG issued its annual solicitation for recommendations for new or modified AKS safe harbors on Dec. 28, 2016. The responses, which were due at the end of February 2017, included a number of proposals by industry groups and manufacturers to implement new safe harbors, or to revise existing ones, to protect so-called value-based or outcome-based pricing arrangements in the pharmaceutical and medical device supply chain. Value-based pricing involves linking payment for a drug or device to patient outcomes and cost-effectiveness, rather than pricing based solely on the volume of sales.

Early in 2016, CMS recognized that value-based pricing should play a role in future drug and device reimbursement when CMS issued its proposed rule on revisions to the Medicare Part B Drug Payment Model, including measures for implementing "value-based tools" to manage reimbursement costs. See 81 Fed. Reg. 13230 (March 11, 2016). Among these tools, CMS explored the use of outcome-based risk-sharing agreements that tie the final price of a drug to results achieved by specific patients in lieu of setting a predetermined price based on historical population data. Under the new approach, manufacturers would agree to provide rebates, refunds or price adjustments if the product does not meet targeted outcomes. Id. at 13244. But a question remains as to how, and whether, these types of arrangements can be structured to comply with federal fraud and abuse statutes, including the AKS, under which even typical volume-based discounting arrangements could technically draw scrutiny if they do not squarely fall within the discount safe harbor.

Commenters urged the OIG to promulgate new stand-alone safe harbors to protect value-based arrangements, so as to encourage, rather than thwart, their development. Moreover, commenters argued that value-based arrangements satisfy factors about which the OIG has historically been concerned, such as promoting access to and quality of care, lowering healthcare costs by aligning financial incentives and fostering competition between manufacturers to innovate the most efficacious products. Recognizing that value-based arrangements may not fit squarely within existing safe harbors, some commenters encouraged expanding existing safe harbors to protect value-based arrangements by, for example, modifying the discount safe harbor to protect arrangements in which a quality or outcome-based discount is offered on a bundle of items and services, or to protect discounts offered in connection with warranties or services provided under a personal or management services contract. They also encouraged the OIG to expand the warranty safe harbor, which currently may only protect product defects, rather than a product's failure to achieve a desired clinical outcome.

While an arrangement is not per se illegal if it does not strictly comply with the requirements of a safe harbor, not having safe harbor protection for value-based arrangements increases the legal and regulatory risk that manufacturers face, thereby limiting their willingness to enter into such arrangements. The industry responded to the OIG's solicitation with a clear and unified message that today's rapidly changing healthcare landscape warrants additional guidance and clarity around value-based arrangements.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions